论文部分内容阅读
前瞻性研究了６５例散瞳患者应用１０μｌ和３０μｌ滴量复方托品酰胺或Ｍｙｄｒｉｎ－Ｐ的散瞳效果。结果表明，点复方托品酰胺组与Ｍｙｄｒｉｎ－Ｐ组两种滴量的瞳孔直径差异均无显著性（Ｐ均＞０．２５），认为１０μｌ滴量的副作用可能更小。
Prospective study of 65 patients with mydriatic application of 10μl and 30μl dose of compound tropicamide or Mydrin-P dilation effect. The results showed that there was no significant difference in pupil diameter between the two groups (P> 0.25) of the two groups of PTOCT and Mydrin-P groups, and the side effect of 10 μL titer was considered to be smaller.